vgr-r01
Gene therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 15, 2022 (NCT05399069)
Timeline
Indications
Mechanism of action
- Cytochrome P450 4V2Supplementation
supplementation - CYP4V2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06699108 | Phase 3 | Dec 1, 2024 | Shanghai Vitalgen BioPharma Co., Ltd. |
| NCT05694598 | Phase 1 | Mar 1, 2023 | Capital Medical University, Shanghai Vitalgen BioPharma Co., Ltd. |
| NCT05399069 | Early Phase 1 (Phase 1) | Sep 15, 2022 | Capital Medical University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 2 | 1 | 1 | 2022 |
| Shanghai Vitalgen BioPharma Co., Ltd. | For profit | 2 | 2 | 2 | 2023 |
2 organizations
Page 1 / 1